Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20959117 | 0.95 | F10 (0.36) | F10DPP4 | |
| SCHEMBL3920197 | 0.81 | CHRNB2 (0.36) | TSHR | |
| SCHEMBL3920202 | 0.81 | CHRNB2 (0.36) | TSHR | |
| SCHEMBL20959020 | 0.79 | CDA (0.38) | RAB9AF10 | |
| SCHEMBL20959070 | 0.79 | F10 (0.38) | NPC1SMN1; SMN2RAB9ATSHRF10 | |
| SCHEMBL5357235 | 0.77 | CHRNB2 (0.35) | DPP4 | |
| SCHEMBL1721165 | 0.77 | CHRNB2 (0.35) | DPP4 | |
| SCHEMBL20958741 | 0.77 | F10 (0.39) | F10DPP4 | |
| SCHEMBL3926724 | 0.77 | CHRNB2 (0.35) | DPP4 | |
| SCHEMBL20959484 | 0.75 | PDE7A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | NPC1 892/4885SMN1; SMN2 146/4885HPGD 2156/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | NPC1 556/4885SMN1; SMN2 115/4885HPGD 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.